V710 + Placebo
Phase 2/3Terminated 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Staphylococcus Aureus
Conditions
Staphylococcus Aureus, Bacteremia, Mediastinitis
Trial Timeline
Dec 1, 2007 → Aug 1, 2011
NCT ID
NCT00518687About V710 + Placebo
V710 + Placebo is a phase 2/3 stage product being developed by Merck for Staphylococcus Aureus. The current trial status is terminated. This product is registered under clinical trial identifier NCT00518687. Target conditions include Staphylococcus Aureus, Bacteremia, Mediastinitis.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00735839 | Phase 1 | Completed |
| NCT00518687 | Phase 2/3 | Terminated |
Competing Products
12 competing products in Staphylococcus Aureus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + Clindamycin | AbbVie | Phase 3 | 77 |
| AZD7760 | AstraZeneca | Phase 1/2 | 41 |
| Daptomycin | Merck | Phase 2 | 52 |
| Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) | Merck | Phase 2 | 52 |
| Imipenem/cilastatin | Pfizer | Approved | 84 |
| linezolid (Zyvox) + vancomycin | Pfizer | Approved | 84 |
| Linezolid + Vancomycin | Pfizer | Pre-clinical | 22 |
| Aurexis® | Bristol Myers Squibb | Phase 2 | 51 |
| Aurexis® (tefibazumab) | Bristol Myers Squibb | Phase 2 | 51 |
| blood samples + nasal swabs | Sanofi | Pre-clinical | 22 |
| Ceftobiprole medocaril + Daptomycin | Basilea Pharmaceutica | Phase 3 | 72 |
| 514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II | XBiotech | Phase 1/2 | 33 |